Brown Advisory’s Novavax NVAX Stock Holding History

Brown Advisory’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,700	Closed	-$16K	–	991
2020 Q2	$16K	Buy	+4,700	New	+$180K	﹤0.01%	940

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brown Advisory's NVAX Position: Q1 2022 in Review

Brown Advisory sold out of Novavax (NVAX) in Q1 2022, closing a stake of 31,822 shares — an estimated $4.55M sold.

Brown Advisory first reported a position in NVAX in Q2 2013 and held it in 35 quarters. The position peaked at $6.96M in Q2 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

Brown Advisory reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
Brown Advisory sold 31,822 Novavax shares in Q1 2022, an estimated $4.55M.
Brown Advisory first reported a position in Novavax in Q2 2013 and held it in 35 quarters.
Brown Advisory's Novavax position peaked at $6.96M in Q2 2021.
381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.